Breakthrough in Personalized mRNA Cancer Vaccine: New Business Opportunity for Moderna?

Moderna (MRNA-US) and Merck & Co. (MSD) have achieved success in a large Phase III clinical trial for their jointly developed personalized mRNA cancer vaccine, marking a landmark breakthrough in tumor immunotherapy and demonstrating the immense commercial potential of mRNA technology beyond respiratory diseases.

The latest trial results show that the vaccine, intismeran autogene, when combined with Merck’s immunotherapy drug Keytruda, significantly reduced the risk of post-surgical recurrence and distant organ metastasis in high-risk melanoma patients. Fueled by this major positive development, Moderna’s stock price surged approximately 177% at the close of U.S. trading, potentially triggering a severe short squeeze. Merck also rose nearly 13%, leading gains among Dow Jones component stocks.

Moderna CEO Stéphane Bancel called the results "an extraordinary milestone for mRNA science." The two companies plan to immediately begin discussions with regulatory agencies regarding marketing authorization applications, with the product potentially gaining approval as early as 2027. Detailed data will be presented at an upcoming international medical conference.

According to Wind Financial News, Wall Street firms including Goldman Sachs, JPMorgan Chase, and Citigroup generally believe in their research reports dated August 19 that this data is the key to unlocking Moderna’s oncology pipeline. However, there is significant divergence among institutions regarding the technology’s commercial prospects and company valuation, with market focus shifting toward the soon-to-be-released detailed efficacy data and its potential application across other cancer types.

Elon Musk posted on social media that mRNA technology still holds enormous potential in curing diseases. "Artificial RNA essentially turns disease treatment into a software problem," he said.

Unlocking the Oncology Pipeline

The Phase III trial named INTerpath-001 is the first study to demonstrate efficacy for a personalized cancer vaccine at the Phase III level. It enrolled 1,137 high-risk melanoma patients who had undergone complete surgical resection, successfully achieving both the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS).

Goldman Sachs believes this is the first positive pivotal clinical data Moderna has obtained outside its respiratory vaccine pipeline, marking the initial unlocking of its oncology vertical. Based on this, Goldman raised the probability of success (PoS) for the vaccine in melanoma to 100% and significantly increased its 12-month target price for Moderna from $67 to $120.

JPMorgan also affirmed the clinical results. The firm noted that achieving DMFS, a key secondary endpoint, carries extremely high clinical value beyond the primary endpoint. Citing melanoma expert Yana Najjar, JPMorgan stated that the DMFS data is "extremely meaningful" and represents the true value proposition of this therapy.

Additionally, principal investigator Georgina Long stated that this combination therapy could establish a completely new treatment paradigm in adjuvant melanoma care.

Commercialization Barriers and Pricing Divergence

Despite the technological breakthrough, Wall Street analysts remain cautious about Moderna’s valuation and commercial execution. JPMorgan maintains a "Underweight" rating with a $40 target price. The firm argues that the market had already priced in success for melanoma (with prior estimated success probability at 85%), and the sharp stock rebound was partly driven by short covering.

Data shows that short positions in Moderna previously accounted for about 13.5% of outstanding shares. JPMorgan emphasizes that while this vaccine, as a partnered asset in a relatively small indication market, is crucial for the company’s return to profitability, the current market cap already fully reflects this expectation.

Citigroup maintains a "Neutral/High Risk" rating with a $60 target price. Citigroup points out that while statistical significance provides a positive visual impression, the hazard ratio (HR), absolute separation, and specific event counts for RFS have not yet been disclosed.

Without these details, it is difficult to assess the magnitude of benefit, durability, and commercial relevance of this therapy in adjuvant melanoma treatment.

Citigroup further stresses that the commercialization threshold for personalized therapies is far higher than that of off-the-shelf standardized drugs. This vaccine requires customized design for each patient’s tumor-specific genetic mutation “fingerprint,” involving synthetic mRNA encoding up to 34 neoantigens. This complex process—including tumor sequencing, manufacturing turnaround time, repeated dosing, and coordination with Keytruda—will pose severe challenges for future commercial rollout.

Cross-Cancer Validation Determines Final Outlook

The success of this Phase III trial in melanoma is seen as a critical juncture for validating the feasibility of the mRNA personalized cancer vaccine platform. According to earlier Bloomberg reports, Jane Healy, head of early oncology development at Merck, said the medical community has pursued therapeutic cancer vaccines for over a century, with the potential advantage of extending patient survival without significantly increasing side effects.

However, whether this technology can be widely applied to other cancers is the core determinant of its ultimate market value. Goldman Sachs is optimistic, believing melanoma success is indicative for other solid tumors. Goldman raised the PoS for non-small cell lung cancer (NSCLC) to 85% and forecasts peak sales of $4.3 billion and $6.6 billion for melanoma and NSCLC respectively (before 50/50 profit sharing with Merck).

Citigroup and JPMorgan are more conservative. Citigroup notes that melanoma is a highly immunogenic tumor with established sensitivity to checkpoint inhibitors, so results cannot be simply extrapolated to cancers like lung, bladder, or kidney cancer. Broad platform validation requires seeing equivalent efficacy in other tumor types and proving that personalized manufacturing can be reliably scaled up.

Currently, Moderna and Merck’s INTerpath program includes nine Phase II and III trials covering multiple cancers such as non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Markets are closely watching the upcoming detailed data and clinical results expected between 2026 and 2027 for other cancer types, which will ultimately determine whether mRNA cancer vaccines can transition fully from scientific "holy grail" to clinical reality.